Lilly’s retatrutide shows substantial weight loss and A1C reduction
Lilly’s triple agonist retatrutide delivered substantial weight loss and A1C reduction, underscoring potential promise for people with obesity and type 2 diabetes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lilly's Retatrutide Shows Promise
Eli Lilly's Retatrutide posts strong phase 3 results, potentially boosting the company's pipeline. This may impact the biotech sector.